DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0033545 A1 Wang (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0033545 A1 Wang (43) Pub US 2011 0033545A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0033545 A1 Wang (43) Pub. Date: Feb. 10, 2011 (54) TOPCAL PHARMACEUTICAL Publication Classification PREPARATIONS HAVING BOTH A NANOPARTICLE SOLUTION ANDA (51) Int. Cl. NANOPARTICLE SUSPENSION AND A6II 3/545 (2006.01) METHODS FOR THE TREATMENT OF A6IR 9/14 (2006.01) ACUTE AND CHRONIC PANTHEREWITH A63L/92 (2006.01) A 6LX 3L/97 (2006.01) (75) Inventor: Changjin Wang, San Diego, CA A6IP 29/00 (2006.01) (US) A6IP 23/02 (2006.01) Correspondence Address: (52) U.S. Cl. ...................... 424/489: 514/226.5: 514/570; FOLEY & LARDNER LLP 514/567 975 PAGE MILL ROAD Palo Alto, CA 94304 (US) (57) ABSTRACT (73) Assignee: ABsize, Inc., Osaka (JP) This invention relates to topical pharmaceutical preparations (21) Appl. No.: 12/844,369 and methods for the treatment of acute and chronic pain and inflammation therewith. The preparations have a saturated (22) Filed: Jul. 27, 2010 Solution of an active pharmaceutical ingredient in a solvent therefor in intimate combination and contact with a Suspen Related U.S. Application Data sion of nanoparticles of the active pharmaceutical ingredient (60) Provisional application No. 61/273,473, filed on Aug. in the solvent, and a pharmaceutically acceptable carrier 6, 2009. therefor, and are administered topically. US 2011/0033545 A1 Feb. 10, 2011 TOPCAL PHARMACEUTICAL will result in better clinical efficacy and reduced side effects, PREPARATIONS HAVING BOTH A which allow for longer-term treatment than current therapies. NANOPARTICLE SOLUTION ANDA NANOPARTICLE SUSPENSION AND SUMMARY OF THE INVENTION METHODS FOR THE TREATMENT OF ACUTE AND CHRONIC PANTHEREWITH 0006. This invention relates to pharmaceutical prepara tions as well as to methods for the treatment of acute and chronic pain and inflammation, and their related symptoms. CROSS-REFERENCE TO RELATED 0007. In one embodiment, this invention relates to phar APPLICATION maceutical preparations comprising a therapeutically effec tive amount of a nanosized non-steroidal anti-inflammatory 0001. This application claims the benefit under 35 U.S.C. drug, and a pharmaceutically acceptable carrier therefor Suit S119(e) of U.S. Provisional Patent Application Ser. No. able for topical administration. The preparations are admin 61/273.473 filed Aug. 6, 2009 which application is incorpo istered topically for the treatment of acute and chronic pain rated herein by reference in its entirety. and inflammation, and their related symptoms. 0008. In another embodiment, the pharmaceutical prepa FIELD OF THE PRESENT INVENTION rations of this invention further comprise an effective amount of a local anesthetic. 0002 This invention relates to topical pharmaceutical 0009. The non-steroidal anti-inflammatory drug is nano preparations. This invention also relates to methods for the sized to nanoparticles of less than 1000 nm, predominately in treatment of acute and chronic pain and inflammation there the range of 200-500 nm or 1-200 nm, preferably 10-100 nm. with. The preparations of this invention have a saturated or 50-100 nm, and most preferably having a mean particle Solution of an active pharmaceutical ingredient in a solvent size of about 40-60 nm (as measured along it longest axis). It therefor in intimate combination and contact with a suspen should be understood that the non-steroidal anti-inflamma sion of nanoparticles of the active pharmaceutical ingredient tory drug is itself nanosized, as opposed to where the medici in the solvent, and a pharmaceutically acceptable carrier nal ingredient is absorbed onto an inert nanosized carrier. therefor suitable for topical administration. 0010. The preparations of this invention are useful in the treatment of acute and/or chronic pain as a result of inflam BACKGROUND OF THE PRESENT INVENTION mation associated with, for example, rheumatoid arthritis, osteoarthritis, inflammatory arthropathies, gout and pseudo 0003. The art is replete with the ways of preparing topical gout, dysmenorrhea, metastatic bone pain, headache and pharmaceutical preparations as well as with dealing with pain migraine, postoperative pain, post-herpetic neuralgia, neuro and inflammation, both in humans and animals. The medical pathic pains, Soft-tissue injuries, strains, sprains, contusions, literature and patents around the world describe many ways in tendonitis or bursitis of the shoulder, elbow, wrist or knee, which these conditions can be treated, with greater or lesser Carpal tunnel syndrome, lateral epicondylosis, lower back Success in any given situation. More recently, many research pains and injury, and the like. It is understood that this inven ers have focused on using Small particles of the active phar tion is not directed to novel non-steroidal anti-inflammatory maceutical ingredient in hope of achieving better clinical agents. Rather, this invention is directed to use of known Success with the enhanced administration that the Smaller, so agents that are being nanosized so as to improve their efficacy called nanoparticles, of the active pharmaceutical ingredient for topical administration. It is also understood that this afford. invention is not treating the diseases referenced above but, 0004 For example, US published application No. 2008/ rather, are treating the inflammation and pain associated 0237376 assigned to ABsize Inc. describes a technique for therewith. creating nanoparticles of an active pharmaceutical ingredient with a laser beam. Related published applications assigned to DETAILED DESCRIPTION OF SPECIFIC ABsize are US published applications 20070284769 and EMBODIMENTS OF THE PRESENT 20080217445. Other laser beam nanosizing techniques are INVENTION shown by Kawakami et al. in US published applications 0011. In one embodiment of this invention, the pharma 20060257489, 20070114306 and 20070152360. However, ceutical preparations comprise a therapeutically effective while these publications describe various techniques for cre amount of nanosized particles of a Solid medicament and, in ating nanoparticles, and using them, for example, in prepar particular, a non-steroidal anti-inflammatory drug selected ing injectable agents, they do not describe topical prepara from the group consisting of aceclofenac, alminoprofen, apa tions or how topical preparations can be effectively utilized in Zone, aspirin, benoxaprofen, butibufen, carprofen, dexketo the treatment of acute pain and inflammation. profen, diclofenac, difenpiramide, diflunisal, droxicam, 0005. It is, therefore, an object of the present invention to enbufen, etodolac, fenoprofen, flufenamic acid, flurbiprofen, provide pharmaceutical preparations that are topically ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, applied as well as to provide methods for the treatment of lornoxicam, meclofenamic acid, mefenamic acid, meloxi acute and chronic pain and inflammation therewith that have cam, nabumetone, naproxen, oxaprozin, phenylbutaZone, higher concentrations of the active pharmaceutical ingredi piroXicam, pirprofen, pranoprofen, Salicylic acid, Sulindac, ent. It is contemplated that the pharmaceutical preparations of Suprofen, tenoxicam, tiaprofenic acid, and tolmetin, and the this invention will allow lower dosages of the active agent to pharmaceutically acceptable salts, and esters thereof, and a be used in comparison with the doses normally administered pharmaceutically acceptable carrier therefor suitable for topi systemically to achieve efficacious results. It is further con cal administration. The preferred class of the non-steroidal templated that the use of lower dosages of the active agent anti-inflammatory drugs is the oxicam class of NSAIDs. The US 2011/0033545 A1 Feb. 10, 2011 presently preferred non-steroidal anti-inflammatory drugs 0016. With regard to the non-steroidal anti-inflammatory are diclofenac, ketoprofen, ketorolac, and piroxicam, with the drugs listed above, this invention contemplates using about presently preferred non-steroidal anti-inflammatory drug 20 mg to about 2,000 mg/day of aceclofenac, preferably being piroXicam. about 200 mg to about 1,000 mg/day, with a specific dose of 0012. In another embodiment of the present invention, the about 600 mg/day; about 9 mg to about 900 mg/day of almi pharmaceutical preparations have a therapeutically effective noprofen, preferably about 90 mg to about 450 mg/day, with amount of nanosized particles of a non-steroidal anti-inflam a specific dose of about 270 mg/day; about 30 mg to about matory drug as set forth above in combination with a local 3,000 mg/day of apaZone, preferably about 300 mg to about anesthetic selected from the group consisting of articaine, 1,500 mg/day, with a specific dose of about 900 mg/day; benzocaine, bupivacaine, dibucaine, etidocaine, levobupiv about 400 mg to about 40,000 mg/day of aspirin, preferably acaine, lidocaine, mepivacaine, piperocaine, prilocaine, ropi about 4,000 mg to about 20,000 mg/day, with a specific dose vacaine, tetracaine, and trimecaine. The presently preferred of about 12,000 mg/day; about 60 mg to about 6,000 mg/day local anesthetics are bupivacaine, lidocaine, prilocaine, and of benoxaprofen, preferably about 600 mg to about 3,000 tetracaine, with the presently preferred local anesthetic being mg/day, with a specific dose of about 1,800 mg/day; about lidocaine. 300 mg to about 30,000 mg/day of butibufen, preferably 0013 The nanoparticles of the non-steroidal anti-inflam about 3,000 mg to about 15,000 mg/day, with a specific dose matory drug can be
Load more

Recommended publications
  • La Hepatotoxicidad Del Droxicam
    Vol. 6, n.º 3 julio - septiembre 1993 butlletí groc Institut Català de Farmacologia Universitat Autònoma de Barcelona La hepatotoxicidad del droxicam Los antiinflamatorios no esteroides (AINE) pue- vía oral a animales de experimentación. 15 Cuando den producir alteraciones hepáticas, que van se disuelve en agua y en medio ácido, así co m o desde aumentos leves, transitorios y subclínicos en el quimo gástrico, se hidroliza inmediatamente de los enzimas hepáticos hasta cuadros bien es- a piroxicam y, según el laboratorio fabricante, se tablecidos de hepatitis citolítica, colostásica o absorbe en forma de piroxicam.16 De hecho, la mixta e, incluso, cuadros de hepatitis crónica. administración de droxicam a animales de labora- to r i o 16 y a seres humanos17 no da lugar a concen- No se conoce exactamente la frecuencia de es- traciones pIasmáticas detectables de droxicam,16 tas reacciones de hepatotoxicidad, pero parece sino de piroxicam. No obstante, se ha podido ser muy baja.1 No obstante, el potencial hepato- comprobar recientemente que tras la administra- tóxico no parece ser el mismo para todos los AINE. En realidad, algunos fueron retirados del ción de droxicam o de piroxicam por vía oral a mercado en los años setenta y ochenta por este ratas, los metabolitos que aparecen en orina no motivo (ibufenac, fenclofenac y benoxaprofeno). son los mismos con ambos fármacos; esto indica- Recientemente en España la Comisión Nacional ría que el metabolismo (probablemente hepático) de Farmacovigilancia recomendó la retirada del no es el mismo y que, por tanto, no se puede mercado del bendazac (Bendalina®), un AINE que, hablar de una equivalencia farmacocinética (y toxi- sin una eficacia clínica bien demostrada, se utili- cológica) absoluta entre los dos fármacos.
    [Show full text]
  • Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan
    Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products.
    [Show full text]
  • Semantic Query Modeling, Context, Section Detection, and Match Score Maximization
    DutchHatTrick: Semantic query modeling, ConText, section detection, and match score maximization. Martijn Schuemie* Dolf Trieschnigg† Edgar Meij‡ ErasmusMC University of Twente University of Amsterdam [email protected] [email protected] [email protected] Introduction This report discusses the collaborative work of the ErasmusMC, University of Twente, and the University of Amsterdam on the TREC 2011 Medical track. Here, the task is to retrieve patient visits from the University of Pittsburgh NLP Repository for 35 topics. The repository consists of 101,711 patient reports, and a patient visit was recorded in one or more reports. Because the training set provided by the track organization was small and not made available until quite late in the competition, we decided to create a small training set ourselves. Not only did this allow us to test several ideas before submitting runs to TREC, it also led to several insights into the data. One finding was that synonyms are widely used. Query expansion was therefore deemed essential to achieve a reasonable performance. Query expansion has been used before in Information Retrieval (IR), and is often divided into statistical and knowledge-based query expansion. Statistical query expansion uses data derived from the corpus itself, and a well-known example is pseudo-relevance feedback [1]. In contrast, we investigated knowledge-based query expansion, which uses a knowledge base such as an ontology or a dictionary to find related terms. This type of query expansion has not always proven to be successful. For instance, Hersh et al. [2] found a decrease in overall search performance when using the Unified Medical Language System (UMLS) [3] to find related terms.
    [Show full text]
  • STUDIES with NON-STEROIDAL ANTI-INFLAMMATORY DRUGS By
    STUDIES WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS by Elizabeth Ann Galbraith M.Sc., C.Biol., M.I.Biol. A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Veterinary Medicine of the University of Glasgow Department of Veterinary Pharmacology M ay 1994 ProQuest Number: 11007888 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007888 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 4kh! TUT GLASGOW UNIVERSITY ) LIBRARY i To Ian ii TABLE OF CONTENTS Acknowledgements v Declaration vi Summary vii List of tables xi List of figures xv Abbreviations xvii Chapter 1 - General Introduction 1 Chapter 2 - General Material and Methods 29 Chapter 3 - Studies with Flunixin 3.1 Introduction 43 3.2 Experimental Objectives 44 3.3 Materials and Methods 45 3.4 Experiments with Flunixin 48 3.5 Results of Oral Experiments with Flunixin 49 3.6 Results of Intravenous Experiments with Flunixin 53 3.7 Results of Subcutaneous Experiments with Flunixin 55 3.8 Discussion 57 3.9 Tables and Figures
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,557,285 B2 Plachetka (45) Date of Patent: *Oct
    US008557285B2 (12) United States Patent (10) Patent No.: US 8,557,285 B2 Plachetka (45) Date of Patent: *Oct. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS FOR (56) References Cited THE COORONATED DELVERY OF NSAIDS U.S. PATENT DOCUMENTS (75) Inventor: John R. Plachetka, Chapel Hill, NC 4,198.390 A 4, 1980 Rider ............................ 424/471 (US) 4.255.431 A 3/1981 Junggren et al. .............. 514,338 (73) Assignee: Pozen Inc., Chapel Hill, NC (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 AU 2006235929 11, 2006 U.S.C. 154(b) by 0 days. CA 2139653 T 2001 This patent is Subject to a terminal dis (Continued) claimer. OTHER PUBLICATIONS (21) Appl. No.: 13/215,855 Goldstein et al., “PN400 significantly improves upper (22) Filed: Aug. 23, 2011 gastrointestinal tolerability compared with enteric-coated naproxen alone in patients requiring chronic NSAID therapy: Results from (65) Prior Publication Data Two Prospective, Randomized, Controlled Trials.” POZEN Inc. sponsored study, 2009. (Document D15 from Letter to European US 2012/OO64156A1 Mar. 15, 2012 Patent Office for counterpart European Application No. 02734602.2, Related U.S. Application Data regarding Oral Proceedings dated Dec. 18, 2009). (60) Division of application No. 12/553,804, filed on Sep. (Continued) 3, 2009, now abandoned, which is a division of application No. 11/129,320, filed on May 16, 2005, Primary Examiner — Nissa Westerberg now Pat. No. 8,206,741, which is a (74) Attorney, Agent, or Firm — Parker Highlander PLLC continuation-in-part of application No.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Aspirin Exacerbated Respiratory Disease
    Journal of Allergy Aspirin Exacerbated Respiratory Disease Guest Editors: Luis M. Teran, Stephen T. Holgate, Hae-Sim Park, and Anthony P. Sampson Aspirin Exacerbated Respiratory Disease Journal of Allergy Aspirin Exacerbated Respiratory Disease Guest Editors: Luis M. Teran, Stephen T. Holgate, Hae-Sim Park, and Anthony P. Sampson Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Marek L. Kowalski, Poland H. Renz, Germany K. Blaser, Switzerland Ting Fan Leung, Hong Kong Nima Rezaei, Iran Eugene R. Bleecker, USA Clare M. Lloyd, UK Robert P. Schleimer, USA J. de Monchy, The Netherlands Redwan Moqbel, Canada Massimo Triggiani, Italy F. Hoebers, The Netherlands Desiderio Passali, Italy Hugo Van Bever, Singapore Stephen T. Holgate, UK Stephen P. Peters, USA A. van Oosterhout, The Netherlands S. L. Johnston, UK David G. Proud, Canada Garry M. Walsh, UK Young J. Juhn, USA F. Rance,´ France Alan P. Knutsen, USA Anuradha Ray, USA Contents Aspirin Exacerbated Respiratory Disease,LuisM.Teran,StephenT.Holgate,Hae-SimPark, and Anthony P. Sampson Volume 2012, Article ID 817910, 2 pages Aspirin Sensitivity and Chronic Rhinosinusitis with Polyps: A Fatal Combination, Hendrik Graefe, Christina Roebke, Dirk Schafer,¨ and Jens Eduard Meyer Volume 2012, Article ID 817910, 10 pages Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease, Maria L. Garcia Cruz, M. Alejandro Jimenez-Chobillon, and Luis M.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs
    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
    [Show full text]
  • Current Prevention and Management of Non-Steroid Anti In.Ammatory
    REVIEW ARTICLE &XUUHQW3UHYHQWLRQDQG0DQDJHPHQWRI1RQVWHURLG $QWL,QÀDPPDWRU\'UXJV$VVRFLDWHG*DVWURHQWHURSDWK\ Fransiscus Ari*, Dadang Makmun** *Department of Internal Medicine, Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo General National Hospital, Jakarta **Division of Gastroenterology, Department of Internal Medicine University of Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta ABSTRACT 1RQVWHURLGDQWLLQÀDPPDWRU\GUXJV 16$,'V DUHWKHPRVWIUHTXHQWO\XVHGGUXJVWRWUHDWLQÀDPPDWLRQ and are used almost in the whole world. However, NSAID is one of the important causes of gastroenteropathy development. NSAIDs enteropathy is frequently undetected because most of them are asymptomatic and required sophisticated examinations to diagnose. Not only non-selective cyclo-oxygenases (COX) inhibitor that can cause NSAID gastropathy, but selective COX-2 inhibitors may also cause gastrointestinal complications. NSAID gastroenteropathy require further evaluation and it may differ between patients. Currently, there is no effective treatment available to treat gastrointestinal damage associated with NSAIDs DGPLQLVWUDWLRQ,GHQWL¿FDWLRQRISURWHFWLYHIDFWRUVLQJDVWURLQWHVWLQDOFRPSOLFDWLRQGXHWR16$,'VXVHLVVWLOOD serious challenge. In this review, we will discuss the effect of NSAID administration towards gastrointestinal system, also the prevention and management strategies. Keywords: QRQVWHURLGDQWLLQÀDPPDWRU\GUXJVJDVWURHQWHURSDWK\&2;LQKLELWRUSUHYHQWLRQWUHDWPHQW ABSTRAK 2EDWDQWLLQÀDPDVLQRQVWHURLG 2$,16 DGDODKREDW\DQJSDOLQJVHULQJGLJXQDNDQXQWXNWHUDSLLQÀDPDVL
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,183,779 B1 10 11 12
    USOO6183779B1 (12) United States Patent (10) Patent No.: US 6,183,779 B1 Ouali et al. (45) Date of Patent: Feb. 6, 2001 (54) STABILIZED PHARMACEUTICAL 5,698,225 12/1997 Gimet et al. ......................... 424/475 COMPOSITION OF ANONSTEROIDAL ANTI-NFLAMMATORY AGENT AND A FOREIGN PATENT DOCUMENTS PROSTAGLANDIN 91/16895 11/1991 (WO). 99/12524 3/1999 (WO). (75) Inventors: Aomar Ouali, Boisbriand; Abul Kalam 99/65496 12/1999 (WO). Azad, Montreal, both of (CA) 00/01368 1/2000 (WO). 00/15200 3/2000 (WO). (73) Assignee: Pharmascience Inc., Montreal (CA) OTHER PUBLICATIONS (*) Notice: Under 35 U.S.C. 154(b), the term of this Searle HealthNet Prescribing Information for Arthrotec(R) patent shall be extended for 0 days. (downloaded from http://www.searlehealthnet.com/pi/ar throtec.html on Oct. 27, 1998). (21) Appl. No.: 09/273,692 Information for the Patient: ControtecTM. (22) Filed: Mar. 22, 1999 * cited by examiner Primary Examiner James M. Spear (51) Int. Cl. ............................... A61K 9/22; A61 K9/24; (74) Attorney, Agent, or Firm-Dianne E. Reed; J. Elin A61 K9/52; A61 K9/54 Hartrum; Reed & Associates (52) U.S. Cl. .......................... 424/472; 424/451; 424/457; 424/458; 424/465; 424/468; 424/470; 424/474; (57) ABSTRACT 424/489; 514/772.3; 514/781; 514/970 A pharmaceutical composition is provided for the oral (58) Field of Search ..................................... 424/472, 474, administration of an NSAID and a prostaglandin. The com 424/451, 464, 465, 489, 470, 457, 468, position is a solid dosage form wherein the NSAID is 458 enterically coated and the prostaglandin is present along with an effective Stabilizing amount of a prostaglandin (56) References Cited Stabilizing agent Such as hydroxypropyl methylcellulose or U.S.
    [Show full text]